{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:52:41Z","timestamp":1783612361523,"version":"3.55.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"AstraZeneca Pharmaceuticals"},{"name":"International Network for Optimal Resistance Monitoring"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/jac\/dky267","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:18:15Z","timestamp":1529320695000},"page":"2777-2781","source":"Crossref","is-referenced-by-count":61,"title":["In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u201315"],"prefix":"10.1093","volume":"73","author":[{"given":"Krystyna M","family":"Kazmierczak","sequence":"first","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn L M","family":"de Jonge","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Stone","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"key\n\t\t\t\t20180921035242_dky267-B1","volume-title":"Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20180921035242_dky267-B2","volume-title":"Antimicrobial Resistance Surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"ECDC","year":"2017"},{"key":"key\n\t\t\t\t20180921035242_dky267-B3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180921035242_dky267-B4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180921035242_dky267-B5","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/AAC.00574-09","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa","volume":"53","author":"Rodriguez-Martinez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B6","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B7","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/AAC.01645-10","article-title":"Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study","volume":"55","author":"Cabot","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B8","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/jac\/dkr232","article-title":"Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem, and doripenem","volume":"66","author":"Riera","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009\u20132011 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime\u200a+\u200aNXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B13","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/AAC.00047-16","article-title":"Identification of novel VEB \u03b2-lactamase enzymes and their impact on avibactam inhibition","volume":"60","author":"Lahiri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B14","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime-avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B17","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B18","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035242_dky267-B19","author":"AstraZeneca Pharmaceuticals","year":"2016"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/10\/2777\/25770325\/dky267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T21:52:16Z","timestamp":1661464336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/10\/2777\/5052243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,7,11]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky267","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,7,11]]}}}